Skip to main content

Advertisement

Table 2 NT-proBNP and BNP measurements

From: Brain natriuretic peptide for prediction of mortality in patients with sepsis: a systematic review and meta-analysis

Marker Study Assay Optimal Timing Cut-off Point (pg/ml) Sensitivity/Specificity AUC Proportion of Elevated BNPs (%)
NT-proBNP Varpula 2007 [28] Roche, Elecsys 2010 analyzer On admission 7090 58/66 0.631 40.6
  Mokart 2007 [29] Roche, Elecsys 2010 analyzer Day 2 after admission 6624 86/77 0.87 54.9
  Roch 2005 [31] Roche, Elecsys 2010 analyzer Within 24 hours after admission 13600 73/83 0.8 48.7
  Brueckmann 2005 [32] Enzyme immunoassay (Biozol) Day 2 after admission 11900 50/90 0.68 21.1
  Sturgess 2010b* [23] Roche, Elecsys 2010 analyzer Within 72 hours after admission 400 83/40 0.67 66.7
BNP Perman 2011 [22] Biosite Diagnostics, Triage On admission 49 63/69 0.69 47.6
  Zhao 2009 [24] Immunofluorescence assay 24 hours after admission 681.4 91.4/80.3 0.915 47.1
  Chen 2009 [25] Biosite Diagnostics, Triage Within 24 hours after admission 113 86/55 0.737 32.1
  Yucel 2008 [26] Immunoradiometric assay, Shionoria On admission 32.1 100/95 0.99 52.5
  Post 2008 [27] Biosite Diagnostics, Triage Day 5 after admission 121 76.3/52.7 0.648 59.1
  Ueda 2006 [30] Immunoradiometric assay, Shionoria Day 2 after admission 650 92/80 0.85 59.1
  Charpentier 2004 [33] Immunoradiometric assay, Shionoria Day 2 after admission 190 70/67 0.66 44.1
  Sturgess 2010a* [23] Biosite Diagnostics, Triage Within 72 hours after admission 254 83/60 0.76 52.4
  1. BNP = brain natriuretic peptide, NT-proBNP = N-terminal pro-B-type natriuretic peptide. *The study reported both BNP (Sturgess 2010a) and NT-proBNP (Sturgess 2010b). Manufacture and kind of assay. The manufacture was not reported. ¶ AUC indicates the area under the receiver operating characteristic curve.